47.92
前日終値:
$48.43
開ける:
$48.84
24時間の取引高:
11.57M
Relative Volume:
0.91
時価総額:
$97.54B
収益:
$47.70B
当期純損益:
$5.07B
株価収益率:
19.32
EPS:
2.48
ネットキャッシュフロー:
$14.58B
1週間 パフォーマンス:
-1.07%
1か月 パフォーマンス:
-0.21%
6か月 パフォーマンス:
-14.17%
1年 パフォーマンス:
+0.63%
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BMY
Bristol Myers Squibb Co
|
47.92 | 98.09B | 47.70B | 5.07B | 14.58B | 2.48 |
![]()
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
2025-04-22 | 開始されました | Piper Sandler | Overweight |
2024-12-16 | アップグレード | Jefferies | Hold → Buy |
2024-12-10 | 再開されました | BofA Securities | Neutral |
2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
2024-10-17 | 開始されました | Bernstein | Mkt Perform |
2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-10-20 | 再開されました | UBS | Neutral |
2023-07-14 | 開始されました | HSBC Securities | Reduce |
2023-07-10 | 開始されました | SVB Securities | Market Perform |
2023-06-28 | 開始されました | Daiwa Securities | Outperform |
2023-03-06 | 開始されました | Jefferies | Hold |
2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
2022-11-18 | 開始されました | Credit Suisse | Neutral |
2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2022-04-06 | 再開されました | Morgan Stanley | Underweight |
2021-12-17 | 開始されました | Goldman | Buy |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-11-01 | ダウングレード | Argus | Buy → Hold |
2021-07-27 | 再開されました | Truist | Buy |
2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | アップグレード | Truist | Hold → Buy |
2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
2020-11-10 | 再開されました | Bernstein | Mkt Perform |
2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-07-28 | 開始されました | Raymond James | Outperform |
2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-01-06 | 再開されました | Citigroup | Buy |
2019-12-13 | アップグレード | Argus | Hold → Buy |
2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
2019-05-28 | 開始されました | Goldman | Buy |
2019-05-20 | ダウングレード | Argus | Buy → Hold |
2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
2019-05-03 | 再開されました | JP Morgan | Overweight |
2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues
Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest
Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review
FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com
Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com
The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies - uk.finance.yahoo.com
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga
Lowe's, Bristol-Myers, and Marvell Technology: Key Research Reports - AInvest
Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology - Yahoo Finance
Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: Market Implications - TipRanks
Bristol-Myers Squibb’s New Study on NSCLC Treatment: Market Implications - TipRanks
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome - TipRanks
Bristol-Myers Squibb and Incyte’s Cancer Study Update: Market Implications - TipRanks
Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks
Bristol-Myers Squibb’s New Psoriasis Study: A Long-Term Safety Evaluation - TipRanks
Anal Cancer Market Is Going to Boom | Major Giants Merck & Co., Roche, Bristol-Myers Squibb, Pfizer - newstrail.com
Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com Nigeria
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr
Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily
Bristol-Myers Squibb’s MYK-224 Study Termination: What Investors Need to Know - MSN
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily
Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN
Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq
Bristol-Myers Squibb’s Promising Phase 3 Study on BMS-986278: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Bristol Myers Squibb (NYSE:BMY) Cut to Neutral at Daiwa Capital Markets - Defense World
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com
Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Dividend Stocks for August 2025 - Morningstar
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha
BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance
BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com
Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):